HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Inal, J. M. Articles by Schifferli, J. A. Search for Related Content PubMed PubMed Citation Articles by Inal, J. M. Articles by Schifferli, J. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

A Peptide Derived from the Parasite Receptor, Complement C2 Receptor Inhibitor Trispanning, Suppresses Immune Complex-Mediated Inflammation in Mice¹

Jameel M. Inal^2,*, Brigitte Schneider^*, Marta Armanini and Jürg A. Schifferli^*

^* Department of Research, University Hospital Basel, Basel, Switzerland; and Primm società a responsabilità limitata, Milan, Italy

Complement C2 receptor inhibitor trispanning (CRIT) is a Schistosoma protein that binds the human complement protein, C2. We recently showed that peptides based on the ligand binding region of CRIT inhibit the classical pathway (CP) of complement activation in human serum, using hemolytic assays and so speculated that on the parasite surface CRIT has the function of evading human complement. We now show that in vitro the C2-binding 11-aa C terminus of the first extracellular domain of CRIT, a 1.3-kDa peptide termed CRIT-H17, inhibits CP activation in a species-specific manner, inhibiting mouse and rat complement but not that from guinea pig. Hitherto, the ability of CRIT to regulate complement in vivo has not been assessed. In this study we show that by inhibiting the CP, CRIT-H17 is able to reduce immune complex-mediated inflammation (dermal reversed passive Arthus reaction) in BALB/c mice. Upon intradermal injection of CRIT-H17, and similarly with recombinant soluble complement receptor type 1, there was a 41% reduction in edema and hemorrhage, a 72% reduction in neutrophil influx, and a reduced C3 deposition. Furthermore, when H17 was administered i.v. at a 1 mg/kg dose, inflammation was reduced by 31%. We propose that CRIT-H17 is a potential therapeutic agent against CP complement-mediated inflammatory tissue destruction.

This article has been cited by other articles:

				J. M. Inal, K.-M. Hui, S. Miot, S. Lange, M. I. Ramirez, B. Schneider, G. Krueger, and J.-A. Schifferli Complement C2 Receptor Inhibitor Trispanning: A Novel Human Complement Inhibitory Receptor J. Immunol., January 1, 2005; 174(1): 356 - 366. [Abstract] [Full Text] [PDF]